<html>
        <head>
            <link rel="stylesheet" type="text/css" href="layout.css" />
        </head>
        <style> 
            .right { 
                margin-left: 160px;
            } 
        </style>
        
        <div class="sidenav">
            <a href="#">About</a>
            <a href="index_gpt.html">Index</a>
        </div>
    <div class="header"><h3>EMPHASIS-HF</h3></div><p><span class="main">"Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms". The New England Journal of Medicine. 2011. 364(1):11-21.  </span></p><p><span class="contents">
                                        Links to original sources:
                                        <a href=https://www.wikijournalclub.org//wiki/EMPHASIS-HF>Wiki Journal Post</a>
                                        <a href=http://www.nejm.org/doi/full/10.1056/NEJMoa1009492>Full Journal Article</a>
                                        </span></p><p><span class="main">Contents
1 Clinical Question
2 Bottom Line
3 Major Points
4 Guidelines
5 Design
6 Population
6.1 Inclusion Criteria
6.2 Exclusion Criteria
6.3 Baseline Characteristics
7 Interventions
8 Outcomes
8.1 Primary Outcome
8.2 Secondary Outcomes
9 Safety 
10 Funding
11 Further Reading
 </span></p><h2><span class="labels">Clinical Question</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">In patients with chronic systolic heart failure and mild symptoms, does the addition of eplerenone improve cardiovascular outcomes?
 </span></p><h2><span class="labels">Bottom Line</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">In patients with chronic systolic heart failure and mild symptoms, the addition of eplerenone reduced the composite outcome of cardiovascular death or hospitalization for heart failure, as well as other critical endpoints including all-cause mortality.
 </span></p><h2><span class="labels">Major Points</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">Mineralocorticoid receptor antagonists such as spironolactone and eplerenone have been shown to improve survival in patients with severe systolic heart failure or following myocardial infarction. The EMPHASIS-HF trial evaluated the addition of eplerenone in patients with chronic systolic heart failure and mild symptoms (NYHA functional class II) and showed significant reductions in cardiovascular outcomes.
 </span></p><h2><span class="labels">Guidelines</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">Current guidelines recommend the use of a mineralocorticoid-receptor antagonist in patients with systolic heart failure (NYHA functional class II-IV) who also have an LVEF ≤35%, following myocardial infarction with LVEF ≤40%, or in patients with diabetes mellitus after myocardial infarction.
 </span></p><h2><span class="labels">Design</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">Multicenter, double-blind, parallel-group, randomized, placebo-controlled trial.
N=2737 patients with chronic systolic heart failure and NYHA class II symptoms.
Interventions: Eplerenone (up to 50 mg daily) vs. placebo.
Follow-up period: Median of 21 months.
 </span></p><h2><span class="labels">Population</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">Inclusion Criteria
 </span></p><p><span class="main">- Age ≥55 years.
- NYHA functional class II heart failure.
- Ejection fraction ≤35%.
- Ongoing treatment with ACE inhibitors or ARBs and beta-blockers at recommended or maximal tolerated doses.
- Hospitalization for a cardiovascular reason within 6 months prior to screening, or elevated BNP or NT-proBNP levels.
 </span></p><p><span class="main">Exclusion Criteria
 </span></p><p><span class="main">- Acute myocardial infarction.
- NYHA class III or IV heart failure.
- Serum potassium level >5.0 mmol per liter.
- Estimated GFR <30 mL/min/1.73 m².
- Need for potassium-sparing diuretic.
- Clinically significant coexisting condition.
 </span></p><p><span class="main">Baseline Characteristics
 </span></p><p><span class="main">- Well-matched groups.
- All patients receiving standard pharmacologic therapy for systolic heart failure.
 </span></p><h2><span class="labels">Interventions</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">- Eplerenone starting dose of 25 mg once daily, increased to 50 mg daily if tolerated and based on serum potassium levels.
- Placebo group on matching dummy treatment.
 </span></p><h2><span class="labels">Outcomes</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">Primary Outcome
 </span></p><p><span class="main">- Combined death from cardiovascular causes or first hospitalization for heart failure.
 </span></p><h2><span class="labels">Outcomes</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">- Hospitalization for heart failure or death from any cause.
- Death from any cause.
- Death from cardiovascular causes.
- Hospitalization for any reason.
- Hospitalization for heart failure.
 </span></p><p><span class="main">Safety 
 </span></p><p><span class="main">- Hyperkalemia was more frequent in the eplerenone group, requiring careful monitoring and adjustment of the study drug dosage.
 </span></p><h2><span class="labels">Funding</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">Supported by Pfizer.
 </span></p><h2><span class="labels">Further Reading</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">For additional information, the following materials are available:
- Supplementary Appendix, available at NEJM.org.
- Reprint requests and other correspondence can be addressed to Dr. Faiez Zannad. </span></p>    	
        <div class="footer">Footer</div>
        </body>
        </html>